FDA Approves ALLOPURINOL SODIUM — Hikma Pharmaceuticals USA Inc.

# FDA Approves Hikma Pharmaceuticals' Intravenous Allopurinol Sodium Formulation Hikma Pharmaceuticals USA Inc. received FDA approval for allopurinol sodium for intravenous administration, expanding the injectable gout and tumor lysis syndrome treatment market beyond oral formulations. The approval enables Hikma to capture additional market share in the hospital and acute care settings where IV administration is clinically preferred.